Vivelle-Dot^® Maintains Steady Therapeutic Levels

Consistent Estradiol Levels Throughout the Dosing Cycle

The design of Vivelle-Dot helps maintain steady therapeutic estrogen levels across a range of doses. In the chart below, C_avg represents the average plasma concentration of estradiol in the blood as determined through pharmacokinetic studies.

Adapted from Figure 1 and Table 1 of the Vivelle-Dot Prescribing Information.
*In a pharmacokinetic study, Vivelle-Dot was shown to be bioequivalent to Vivelle. Vivelle is no longer commercially available.
^† Non–baseline-corrected data. Mean plasma concentration levels following application to the abdomen.
^‡ Average plasma concentration.

Vivelle-Dot Has Quick Onset of Action

Therapeutic levels of estradiol may be achieved within 4 hours of first application.

• Estradiol levels remain consistent throughout the dosing cycle